Written by Jane Aubrey
FDA has approved Lisraya, or brepocitinib, tablets for adults with dermatomyositis, creating the first FDA-approved oral treatment option for this rare autoimmune disease. The August 27 approval was granted to Priovant Therapeutics. It matters because people with dermatomyositis have long had limited disease-specific options and often relied on treatments developed for other conditions. An approved oral therapy gives clinicians and patients a new labeled alternative, but it does not make treatment selection routine or risk-free.
Dermatomyositis causes chronic inflammation that can affect muscle strength and skin, producing progressive weakness and characteristic rashes. Lisraya is a once-daily Janus kinase and tyrosine kinase 2 inhibitor, or JAK/TYK2 inhibitor. FDA says the drug works by blocking JAK pathways that play an important role in immune and inflammatory responses. Mechanistic plausibility, however, is not enough for a regulatory decision; the key evidence is whether treatment improves measures that matter in a controlled trial.
FDA evaluated efficacy and safety in NCT05437263, a Phase 3 randomized, double-blind, multicenter, placebo-controlled study of 241 adults. Participants received brepocitinib 30 mg once daily, 15 mg once daily or placebo over 52 weeks. The primary clinical assessment was the Total Improvement Score at week 52. This composite tracks change across six domains: muscle strength, physical function, skin and other disease activity, muscle enzymes, and physician and patient assessments of overall health.
The agency reports that participants receiving the 30 mg dose had a higher average Total Improvement Score than placebo at week 52. It also reports improvement in physical function and skin disease activity, plus a higher likelihood of corticosteroid reduction by week 48. These results create an evidence-based option, but the FDA announcement does not turn a composite endpoint into a universal promise. Individual response can vary, and the full prescribing information, baseline disease severity, concurrent conditions and patient goals remain central to decisions in practice.
Safety is especially important for this class. FDA lists upper respiratory tract infection, headache, fatigue, urinary tract infection and nausea among the most common adverse reactions. In the 30 mg arm, discontinuation due to adverse reactions occurred in 6% of participants, compared with 11% in the placebo group. That contrast should be interpreted carefully: a discontinuation rate is not a complete safety profile, and it does not offset the need to consider serious risks across the treatment population.
Lisraya carries a boxed warning for serious infections, increased all-cause mortality, malignancies, major adverse cardiovascular events and thrombosis. A boxed warning is a prominent regulatory risk communication, not a reason to ignore the treatment’s potential benefit. It is a reason for informed selection, screening, monitoring and discussion of alternatives. The approval also carried Orphan Drug and Priority Review designations, reflecting the rare-disease context and the agency’s expedited-review pathway.
The next chapter is real-world implementation. Dermatology, rheumatology, neurology, pharmacy and primary-care teams will need to coordinate diagnosis, baseline assessment, infection-risk management, medication review and follow-up. The value of an oral therapy may include convenience, but convenience should not eclipse the monitoring requirements attached to a JAK/TYK2 inhibitor. Post-approval data and clinical experience will help clarify how trial findings translate across varied disease manifestations and patient populations.
This article is news analysis, not medical advice. Treatment decisions should be made with qualified clinicians using current, approved-label information.
